Diffuse large XXXX with mediastinal mass at presentation.

@entity1 @entity5948 @entity1892 @entity3012
UNASSIGNED: 6585 Background: Primary mediastinal @entity1892 (PMBL) has been recognized as a subtype of @entity1892 ( @entity1892 ) with distinct characteristics (e.g.: seen most often in young females) and is thought to be of thymic origin. Other subtypes of @entity1892 may involve the mediastinum and may be confused with PMBL. The value of radiotherapy in @entity1892 with a mediastinal mass is debated. We conducted this retrospective analysis to study clinical characteristics and treatment outcomes in @entity1 with @entity1892 and a mediastinal mass at presentation. METHODS: This is an analysis of 61 @entity1 diagnosed with diffuse large @entity1892 presenting with a mediastinal mass> 5 cms who received their initial treatment between June 1984 and October 2000. RESULTS: The median age was 41 years and 50% were females. 66% presented with elevated LDH and 63% had limited stage disease (stage I and II). 46 % of the @entity1 presented with mediastinal mass >10cms and 69% had B symptoms. 27% received adjuvant radiation therapy. All @entity1 received @entity5948 -containing chemotherapy. A complete remission was achieved in 62% and partial remission in 22% of the @entity1 . The median follow-up of surviving @entity1 is 7.6 years and the 5-year overall ( @entity3012 ) and event-free survival (EFS) is 55% and 38%, respectively. Older @entity1 had significantly poorer @entity3012 (p = 0.016), but age was not associated with EFS. Stage III and IV @entity1 had poorer outcome compared to stage I and II (EFS 58% vs. 24%, p = 0.025 and @entity3012 84% vs. 30%, p < 0.001). Tumor size, B symptoms, LDH and number of extra nodal sites were not significantly associated with outcome. @entity1 who received adjuvant radiation therapy compared to those who did not had better EFS (65% vs. 32%, p< 0.01), and @entity3012 (72% vs. 45%, p = 0.081). The use of radiation therapy improved outcome in @entity1 with stages I and II and not in III and IV. The advantage was most pronounced for stage II @entity1 (EFS p = 0.014 and @entity3012 p= 0.013). CONCLUSIONS: @entity1 with @entity1892 with mediastinal mass who present with limited stage disease benefit from adjuvant radiation therapy. No significant financial relationships to disclose.
